X
<

Johnson & Johnson's 1Q18 Earnings: What to Expect on April 17

PART:
1 2 3
Part 3
Johnson & Johnson's 1Q18 Earnings: What to Expect on April 17 PART 3 OF 3

Analysts’ Recommendations for Johnson & Johnson on April 16

Wall Street analysts’ estimates

Johnson & Johnson (JNJ) reported revenues of $20.2 billion during 4Q17—11.5% growth compared to 4Q16. Wall Street analysts expect Johnson & Johnson to generate earnings per share of $2.00 on revenues of $19.4 billion in 1Q18—9.2% revenue growth compared to $17.8 billion in 1Q17. The revenue growth is expected to be driven by increased sales across all three business segments.

Analysts&#8217; Recommendations for Johnson &#038; Johnson on April 16

Interested in AMGN? Don't miss the next report.

Receive e-mail alerts for new research on AMGN

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

The above chart shows analysts’ recommendations in the past 12 months.

Analysts’ ratings

Johnson & Johnson’s stock price has decreased nearly 6.5% in the last 12 months. Analysts estimate that the stock might increase 13.8% in the next 12 months. Wall Street analysts’ recommendations show a 12-month target price of $148.67 per share—compared to the last price of $130.62 per share as of April 13, 2018.

As of April 16, 2018, there are 23 analysts tracking Johnson & Johnson. Five analysts recommend a “strong buy,” seven analysts recommend a “buy,” eight analysts recommend a “hold,” two analysts recommend a “sell,” and one analyst recommends a “strong sell.” The consensus rating for Johnson & Johnson stands at 2.43, which represents a moderate “buy” for value investors.

Notably, the iShares Core High Dividend ETF (HDV) holds 5.7% of its total investments in Johnson & Johnson, 5.1% in Pfizer (PFE), 3.4% in Merck & Co. (MRK), and 2.1% in Amgen (AMGN).

Check out all the data we have added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data as well as dividend info. Take a look!

X

Please select a profession that best describes you: